News - Page 8 of 12 - Leukaemia Care

10th September 2019

SMC approves Kymriah CAR-T therapy for use on the NHS in Scotland for DLBCL patients

Yesterday, the Scottish Medicines Consortium approved the use of tisagenlecleucel-T (brand name Kymriah), on the NHS in Scotland, for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of CAR-T cell therapy.

13th August 2019

SMC approves venetoclax with rituximab for relapsed/refractory CLL patients in Scotland

The Scottish Medicine Consortium (SMC) has announced that it is recommending the use of venetoclax with rituximab on the NHS for chronic lymphocytic leukaemia (CLL) patients who have had at least one prior therapy. Read more about this decision in our article.

8th July 2019

Scottish Medicine Consortium (SMC) approve arsenic trioxide for NHS patients in Scotland.

The Scottish Medicines Consortium (SMC) have today announced that arsenic trioxide is recommended for NHS acute promyelocytic leukaemia (APL) patients in Scotland. Find out what this decision means for patients in our article.

21st June 2019

The National Institute of Health and Care Excellence (NICE) recommends the use of blinatumomab

The National Institute of Health and Care Excellence (NICE) have recommended the use of blinatumomab for Philadelphia chromosome negative (Ph-ve), CD19 positive, B cell precursor acute lymphoblastic leukaemia (ALL), who have MRD of at least 0.1%.

11th March 2019

Scottish Medicines Consortium has not approved the use of Tisagenlecleucel-T for diffuse large-B cell lymphoma (DLBCL)

Today, the Scottish Medicines Consortium (SMC) has not approved the use of Tisagenlecleucel-T (brand name Kymriah) on the NHS in Scotland for patients with diffuse large-B cell lymphoma (DLBCL). Kymriah is a brand of chimeric antigen receptor (CAR) T-cell therapy and is manufactured by Novartis.

11th March 2019

Liposomal cytarabine with daunorubicin approved for use in Scotland for t-AML and AML-MRC

The Scottish Medicines Consortium (SMC) has today recommended the use of liposomal cytarabine with daunorubicin to treat previously untreated therapy-related AML (t-AML) and AML with myelodysplastic changes (AML-MRC).

11th February 2019

Scottish Medicines Consortium approves Kymriah to be funded for use on the NHS in Scotland

Kymriah is a brand of CAR-T therapy, a pioneering new treatment for blood cancer patients. Find out more about the approval, and who it will benefit, here.

18th January 2019

NICE approves venetoclax (VENCLYXTO) with rituximab for previously treated chronic lymphocytic leukaemia (CLL) patients

NHS England are to make the first targeted CLL chemotherapy-free combination treatment of a fixed duration available through routine commissioning to treat patients relapsing or failing a first treatment

14th January 2019

Arsenic trioxide for APL in Scotland

The Scottish Medicines Consortium (SMC) have today announced that arsenic trioxide is not recommended for NHS patients in Scotland. Find out more about this decision and how it affects acute promyelocytic leukaemia (APL) patients.

19th December 2018

Liposomal cytarabine and daunorubicin approved by NICE

The National Institute of Health and Care Excellence (NICE) have today recommended the use of liposomal cytarabine with daunorubicin to treat previously untreated therapy-related AML and AML with myelodysplastic changes.